Metastatic Cancer Clinical Trial
Official title:
Prognostic Factors Associated With Successful Omission of Whole Brain Radiotherapy in Patients With 4 or Less Cerebral Metastases Treated With Focal Radiation or Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells in a single high
dose. Combining radiation therapy with surgery may be a more effective treatment for brain
metastases.
PURPOSE: Clinical trial to study the effectiveness of radiation therapy with or without
surgery in treating patients who have brain metastases.
OBJECTIVES:
- Develop prognostic factors for patients with brain metastases treated by focal treatment
without concurrent whole brain irradiation.
- Determine whether focal treatment without whole brain radiotherapy produces good
long-term outcome in patients with four or less cerebral metastases.
- Assess survival, physical and cognitive functioning, and quality of life of patients
treated on this protocol.
OUTLINE: Quality of life is assessed using the FACT-BR scale, physical function is assessed
using the FIM scale, and cognition is assessed using two brief pencil and paper tests.
Patients receive focal therapy for cerebral metastases by any combination of (1) surgery plus
fractionated stereotactic radiotherapy to surgical bed, or (2) single fraction stereotactic
radiotherapy by linear accelerator with or without a radiation sensitizer.
Patients are followed at 2 and 10 weeks, then every 3 months for 18 months, then every 6
months for 3 years, then annually. Quality of life is assessed at each followup visit.
Patients suffering intracerebral relapse are offered further focal therapy if they have no
more than 3 metastases, no more than 6 lesions over consecutive scans, and continue to have
life expectancy of at least 3 months and Karnofsky performance status of 60-100%. Otherwise,
relapsed patients are offered whole brain radiotherapy or supportive treatment with steroids,
and may also receive stereotactic boost to the new lesions. Patients who have received prior
whole brain irradiation will be offered entry into other protocols if eligible or supportive
treatment with steroids. Patients are followed as above.
PROJECTED ACCRUAL: At least 60 patients will be enrolled in this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
| Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
| Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
| Not yet recruiting |
NCT03058809 -
Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
| Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
| Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
| Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |